ANN ARBOR, Mich., Jan. 19, 2018 -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the Company succeeded in creating a new hybrid transgenic silkworm at its Michigan production facility. This is the first hybrid silkworm created at the new Michigan facility, which recently opened in October of 2017.
This is the first new hybrid line developed in conjunction with the Company’s US Army contract and is the next step in its program to expand its commercial recombinant spider silk offerings. The new recombinant spider silk strain combines properties from one of the Company’s best performing transgenics with a large commercial silkworm line, to produce larger cocoons and even stronger silk.
“Creating our first hybrid in the new facility is a great moment for the Company,” said Jon Rice, COO. “The transgenic line that we used, as the base for this new hybrid, has been under development for some time. We are very eager to review the test results for this new line, as they come in. The opportunity to soon analyze its capabilities, once transformed into a commercial line, are very exciting.”
To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (w), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
[email protected]


Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Washington Post Publisher Will Lewis Steps Down After Layoffs
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 



